Michael Buck as Executive Vice President and Chief Commercial Officer at HeartFlow

Attention Deficit Hyperactivity Disorder: A Drug Can Relieve Persistent Daydreaming, Fatigue, and Brain Sluggishness in Adults

Researchers at NYU Grossman School of Medicine and Icahn School of Medicine at Mount Sinai who led the study say the stimulant lisdexamfetamine (sold as Vyvanse) reduced by 30 percent self-reported symptoms of sluggish cognitive tempo. It also lowered by over 40 percent symptoms of ADHD and significantly corrected deficits in executive brain function, with fewer episodes of procrastination, improvements in keeping things in mind, and strengthened prioritization skills.

Lucida Medical (Cambridge University Spin-out) Joins GE Healthcare Edison™ Accelerator Programme

Lucida Medical was invited to join the Edison Accelerator programme for its pioneering work in helping identify prostate cancer and its exceptional development team led by Prof Evis Sala and Dr Antony Rix, both highly experienced in artificial intelligence, or AI, medical technology.


HeartFlow Inc. today announced the appointment of Michael Buck as executive vice president and chief commercial officer.  The company reports that effective immediately, Buck will be responsible for expanding and accelerating global market adoption of the company’s HeartFlow® FFRct Analysis, the first noninvasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart.

John H. Stevens, M.D., chairman and CEO of HeartFlow on Buck: “Mike brings of wealth of valuable commercial leadership experience to HeartFlow at a pivotal growth time for the company.”  Executive caliber, “We are thrilled to be adding a professional of his caliber to our executive management team, and look forward to his help in bringing the HeartFlow FFRct Analysis to every physician and patient who could benefit from it in markets worldwide.”

The company cites: Michael Buck brings to HeartFlow 25 years of operational experience in global business and product development, licensing and acquisitions, venture investment and commercial sales management. He most recently served as president of the medical products division for Cardinal Health, with global responsibility for the Cardinal brand product portfolio. Prior to Cardinal Health, Buck held several senior leadership roles at Abbott Laboratories, including vice president of global market development, vice president of licensing and acquisitions, and vice president of venture investing. He has also held commercial leadership positions at Novoste Corporation, Boston Scientific and Smith & Nephew.

“HeartFlow’s technology stands to change the way coronary artery disease is diagnosed and managed in health settings across the world,” said Buck. “I am honored to be part of a team with a proven solution that not only improves patient experience and population health, but also drives significant unnecessary cost out of the healthcare system.”



Trinity Health Names Mark LePage, M.D., as Senior Vice President of Medical Groups and Ambulatory Strategy

Prior to his time at IHA, LePage served as chief medical officer of Marshfield Clinic in Wisconsin

Jody Crane, MD Recognized by Modern Healthcare As One of the 50 Most Influential Clinical Executives

Dr. Crane’s work to streamline operations positioned and prepared TeamHealth and its clinicians to face the COVID-19 pandemic. Under Dr. Crane’s leadership, TeamHealth was able to maintain high levels of clinical quality throughout the rapidly changing COVID environment.

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

Subscribe to Medical Device News Magazine here.

Related Articles